(Total Views: 598)
Posted On: 04/17/2020 10:05:22 PM
Post# of 154105
Blafarm,
I see you have been doing a good DD. Only way to survive in the Biotech world
.
Thanks for providing the links, will follow them.
The influenza connection was honestly a surprise for me today. Had explored (and posted) about the potential market of CAP (Community Acquired Pneumonia) because:
As Leronimab addresses IL-6 overexpression, we could theorize that it will be helpful.
Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073574/
In regards to the SP calculations, I am glad you reached the same results !!!. I used a times peak sells with a percentage and divided by the number of shares. Your calculation is more accurate but the problem is, as always, the P/E ratio for a BioTech company, the current BioTech P/E (481 companies) is 32.19 But is all over the place, as you can understand (and you tried to do a conservative estimate).
Whatever the case might be, the SP is likely around the value we calculated and this, only for influenza !!. Let's not think where are we sitting with COVID, HIV, Oncology, NASH, Pneumonia thrown in.
Sorry, I shouldn't have said that we don't know where we are sitting. We are sitting at the end of the rainbow, if you know what I mean
A great weekend for all !!!. We are in our way ....
I see you have been doing a good DD. Only way to survive in the Biotech world
. Thanks for providing the links, will follow them.
The influenza connection was honestly a surprise for me today. Had explored (and posted) about the potential market of CAP (Community Acquired Pneumonia) because:
Quote:
In serious cases of infection, the COVID-19 virus invades the cells that line the respiratory tract and lungs and enters the mucus, causing pneumonia. Severe lung damage from pneumonia can result in acute respiratory distress syndrome (ARDS), which in turn can cause septic shock.
As Leronimab addresses IL-6 overexpression, we could theorize that it will be helpful.
Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073574/
In regards to the SP calculations, I am glad you reached the same results !!!. I used a times peak sells with a percentage and divided by the number of shares. Your calculation is more accurate but the problem is, as always, the P/E ratio for a BioTech company, the current BioTech P/E (481 companies) is 32.19 But is all over the place, as you can understand (and you tried to do a conservative estimate).
Whatever the case might be, the SP is likely around the value we calculated and this, only for influenza !!. Let's not think where are we sitting with COVID, HIV, Oncology, NASH, Pneumonia thrown in.
Sorry, I shouldn't have said that we don't know where we are sitting. We are sitting at the end of the rainbow, if you know what I mean
A great weekend for all !!!. We are in our way ....
(5)
(0)
